window.pageData = {"stock":{"_id":3000000023592,"name":"中信保诚中证800医药指数型证券投资基金（LOF）","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","status":"normal","indexFundFlag":1,"lofFundFlag":1,"stockCode":"023592","tickerId":23592,"shortName":"中信保诚中证800医药指数（LOF）E","currency":"CNY","exchange":"jj","masterFundFlag":null,"activeFundFlag":null,"etfFundFlag":null,"pensionTargetFlag":null,"feederFundFlag":null,"classificationFlag":null,"closedEnd":null,"fundCollectionId":4000050490000,"inceptionDate":"2025-03-06T16:00:00.000Z","pinyin":"zxbczz800yyzsxzqtzjj(lof)","followedNum":0,"indexId":1000000000841,"index":{"stockCode":"000841","areaCode":"cn","stockType":"index","exchange":"sh","tickerId":841,"name":"800医药","rebalancingFrequency":"semi-annually"},"fundCollection":{"exchange":"jjgs","stockType":"fund_collection","stockCode":"50490000","tickerId":50490000,"name":"中信保诚基金管理有限公司"},"managers":[{"name":"黄稚","stockType":"fund_manager","stockCode":"8801601333","exchange":"fm","tickerId":826180280}],"hotMetrics":{"fss":{"stockId":3000000023592,"type":"fss","last_data_date":"2025-12-30T16:00:00.000Z","f_ins_h_s_r":0,"f_ind_h_s_r":1,"f_h_a":387,"f_ind_h_s_r_c_hy":0,"f_ins_h_s_r_c_hy":0},"fpr":{"stockId":3000000023592,"type":"fpr","f_cagr_p_r_fs_ssc":5896,"f_cagr_p_r_fs_ssrp":0.5469041560644614,"f_p_r_m1_ssc":5828,"f_p_r_m1_ssrp":0.787883988330187,"f_p_r_m3_ssc":5700,"f_p_r_m3_ssrp":0.7836462537287243,"f_p_r_m6_ssc":5410,"f_p_r_m6_ssrp":0.8434091329266038,"f_p_r_fys_ssc":5565,"f_p_r_fys_ssrp":0.8075125808770669,"f_p_r_y1_ssc":4647,"f_p_r_y1_ssrp":0.8303917348256564},"fp":{"stockId":3000000023592,"type":"fp","last_data_date":"2026-05-20T16:00:00.000Z","f_cagr_p_r_fs":0.07620859232508459,"f_p_r_m1":-0.037959549666234715,"f_p_r_m3":-0.05583259998044365,"f_p_r_m6":-0.05463089876639948,"f_p_r_fys":-0.04044519526980095,"f_p_r_y1":0.03316927027605554},"ff":{"stockId":3000000023592,"type":"ff","f_fr_d":"2025-11-27T16:00:00.000Z","f_m_fr":0.01,"f_c_fr":0.002,"f_mac_fr":0.012},"f_nlacan":{"stockId":3000000023592,"type":"f_nlacan","f_nv_d":"2026-05-20T16:00:00.000Z","f_nv":0.9656,"f_nv_cr":0.003116559318512291},"f_as":{"stockId":3000000023592,"type":"f_as","f_tas":1379784.2696,"f_tas_d":"2026-03-30T16:00:00.000Z"}},"masterSlaveFunds":[{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1},{"_id":3000000013080,"name":"中信保诚中证800医药指数型证券投资基金（LOF）","fundSecondLevel":"company","stockType":"fund","areaCode":"cn","market":"a","exchange":"jj","fundStatus":"normal","indexFundFlag":1,"lofFundFlag":1,"classificationFlag":null,"stockCode":"013080","tickerId":13080,"shortName":"中信保诚中证800医药指数（LOF）C","currency":"CNY","__csrcFundId":3466,"lastUpdated":"2026-05-15T17:09:00.487Z","inceptionDate":"2021-08-25T16:00:00.000Z","fundCollectionId":4000050490000,"followedNum":4,"status":"normal","masterFundFlag":null,"activeFundFlag":null,"closedEnd":null,"etfFundFlag":null,"feederFundFlag":null,"pensionTargetFlag":null,"pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"indexId":1000000000841}],"shareholdings":[{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000165519,"stockId":603259,"holdings":295674,"marketCap":29005619,"netValueRatio":0.1597,"quarterlyChange":0.08230361871138547,"stock":{"stockCode":"603259","exchange":"sh","stockType":"company","tickerId":603259,"name":"药明康德"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000165519,"stockId":600276,"holdings":433384,"marketCap":23931464,"netValueRatio":0.1317,"quarterlyChange":-0.07302333389289883,"stock":{"stockCode":"600276","exchange":"sh","stockType":"company","tickerId":600276,"name":"恒瑞医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000165519,"stockId":2001,"holdings":184969,"marketCap":6390678,"netValueRatio":0.0352,"quarterlyChange":0.37157602223104447,"stock":{"stockCode":"002001","exchange":"sz","stockType":"company","tickerId":2001,"name":"新和成"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000165519,"stockId":538,"holdings":107429,"marketCap":5893554,"netValueRatio":0.0324,"quarterlyChange":-0.03347427766032407,"stock":{"stockCode":"000538","exchange":"sz","stockType":"company","tickerId":538,"name":"云南白药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000165519,"stockId":600436,"holdings":36299,"marketCap":5484778,"netValueRatio":0.0302,"quarterlyChange":-0.10475174783742203,"stock":{"stockCode":"600436","exchange":"sh","stockType":"company","tickerId":600436,"name":"片仔癀"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000165519,"stockId":2422,"holdings":134700,"marketCap":4672743,"netValueRatio":0.0257,"quarterlyChange":0.1819420783645651,"stock":{"stockCode":"002422","exchange":"sz","stockType":"company","tickerId":2422,"name":"科伦药业"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000165519,"stockId":2294,"holdings":67100,"marketCap":4113901,"netValueRatio":0.0226,"quarterlyChange":0.23733602421796118,"stock":{"stockCode":"002294","exchange":"sz","stockType":"company","tickerId":2294,"name":"信立泰"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000165519,"stockId":600196,"holdings":153048,"marketCap":4075668,"netValueRatio":0.0224,"quarterlyChange":0.005285013212534162,"stock":{"stockCode":"600196","exchange":"sh","stockType":"company","tickerId":600196,"name":"复星医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000165519,"stockId":963,"holdings":105540,"marketCap":3727672,"netValueRatio":0.0205,"quarterlyChange":-0.1046894803548798,"stock":{"stockCode":"000963","exchange":"sz","stockType":"company","tickerId":963,"name":"华东医药"}},{"date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","fundId":3000000165519,"stockId":2252,"holdings":639195,"marketCap":3720114,"netValueRatio":0.0205,"quarterlyChange":-0.07979659984826115,"stock":{"stockCode":"002252","exchange":"sz","stockType":"company","tickerId":2252,"name":"上海莱士"}}]},"list":[{"_id":"69e7d5a36201787ae129f707","date":"2026-03-30T16:00:00.000Z","declarationDate":"2026-04-20T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2026年一季度，海外方面，中东地缘冲突激化并持续发酵，能源价格快速上涨并保持高位，美联储降息预期大幅降温，美元指数走强，黄金价格回调，风险资产普遍承压。国内方面，经济呈现温和复苏态势。1-2月国内金融、经济数据均好于预期，3月PMI回升至荣枯线以上，外需韧性较强，内需温和修复。  受中东局势影响，市场风险偏好承压。报告期内，A股权益市场震荡调整，上证指数下跌1.94%，沪深300指数下跌3.89%，中证500指数上涨2.03%，创业板指数下跌0.57%，科创50指数下跌6.54%。行业方面，煤炭、石油石化等能源类行业本期收益居前，而非银金融、商贸零售等行业收益居后。随着市场调整，红利资产表现出较好的防御属性，中证红利指数上涨4.07%，中证国企红利指数上涨4.02%。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。基金管理人认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购，力争获取收益增厚的机会。","lastUpdated":"2026-04-21T19:53:07.840Z","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2026年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1470141","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69ca14380daeb17084fb2b68","date":"2025-12-30T16:00:00.000Z","declarationDate":"2026-03-29T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2025年，海外方面，美联储下半年三次降息为全球市场提供宽松的流动性，美债利率震荡下行，美元指数走弱，黄金价格持续上行。国内方面，经济总体保持平稳运行，全年GDP同比增长5%，增长目标顺利完成。外需维持韧性，出口拉动下生产端偏强，但内生增长动能仍有待加强。固定资产投资增速由正转负，其中房地产影响较为明显，社零增速有所放缓。  2025年，A股市场在4月初受美国关税因素干扰经历快速调整，随后贸易冲突缓和，流动性相对充裕，风险偏好有所提升，权益市场震荡上行。报告期内，上证指数上涨18.41%，沪深300指数上涨17.66%，中证500指数上涨30.39%。从行业上看，受益于海外流动性宽松和全球人工智能技术发展，有色金属、通信、电子等行业涨幅居前，而食品饮料、煤炭等行业表现较弱。报告期内，市场预期有所改善，风险偏好持续提升，成交量有所放大，小盘、成长风格表现相对占优，而传统红利风格表现弱势。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。基金管理人认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购，力争获取收益增厚的机会。","lastUpdated":"2026-03-30T06:12:08.768Z","mo":"去年在全球流动性宽松的环境下，A股权益市场上涨，总体估值水平提升，权益资产风险溢价有所降低。今年市场逻辑可能从估值提升转向盈利驱动，产业或者公司的基本面兑现能力或成为投资中的重要考量。 展望后市，全球经济或延续温和复苏态势，流动性宽松、国内政策支持、盈利修复预期等因素有望共同支持权益市场信心。美联储降息仍有空间，海外流动性有望延续宽松。人民币资产相对吸引力提升，居民财富有增配权益资产趋势，市场流动性预计仍保持相对充裕，将为估值提供支撑。2026年作为“十五五”规划的开局之年，预计政策稳步发力，有望进一步提振市场预期。随着价格因素改善、经济名义增速回升，经济基本面和企业盈利有望延续修复。后续仍需关注全球货币政策和贸易政策变化，以及国内政策出台和实施的节奏、力度与效果。","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2025年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1452361","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb0599730","date":"2025-09-29T16:00:00.000Z","declarationDate":"2025-10-26T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2025年三季度，海外方面，美联储9月降息25个基点符合市场预期，但美联储主席表态偏鹰，美国经济数据维持韧性，后续降息路径仍存不确定性。国内方面，7、8月固投和消费有所走弱，内生动能有待增强，外需出口仍有韧性。流动性维持宽松，政策延续结构性发力。  报告期内，随着贸易冲突缓和，流动性相对充裕，市场风险偏好持续修复，权益市场持续上行。上证指数上涨12.7%，沪深300指数上涨17.9%，中证500指数上涨25.3%。从行业上来看，通信、电子、电力设备、有色金属等行业涨幅居前，而银行、交通运输、石油石化等行业表现较弱。报告期内，市场对经济乐观预期有所升温，市场风格逐步转向大盘成长。市场呈现结构化行情，科技板块表现强势，红利资产表现疲弱。中证红利指数上涨0.9%，中证国企红利指数上涨0.2%。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购，力争获取收益增厚的机会。","lastUpdated":"2026-03-09T14:28:01.043Z","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2025年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1371926","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb059972f","date":"2025-06-29T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2025年上半年，美联储暂停降息，市场对于美国经济前景的担忧上升，美国关税政策加剧全球贸易不确定性，美债利率维持高位震荡，美元指数回落，风险资产的价格波动有所加大，避险情绪推动黄金价格上行。国内方面，经济运行总体保持平稳。消费维持韧性，制造业投资、广义基建投资增速下行但仍处于较高水平，而房地产投资继续承压。上半年受美国关税政策影响，抢出口支撑下出口数据韧性较强。 报告期内，A股市场整体波动较大，4月初受美国关税因素干扰、市场经历快速调整，随后震荡上行。上证指数上涨2.76%，沪深300指数上涨0.03%，中证500指数上涨3.31%。从行业上看，有色、银行、国防军工、传媒等行业涨幅居前，而煤炭、食品饮料、房地产等行业表现较弱。报告期内，小盘、成长风格表现相对占优。红利资产内部出现结构分化、作为机构配置重要方向之一的银行板块表现较好。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购，力争获取收益增厚的机会。","declarationDate":"2025-07-17T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.040Z","mo":"市场经历4月初的快速调整后，随着贸易冲突缓和、地缘风险阶段性平息，叠加流动性相对充裕，市场风险偏好持续修复。展望后市，外部宏观不确定性依然存在，美国关税政策和贸易冲突或仍有反复，但对市场影响可能有所减弱。下半年美联储降息的概率依然较高，仍需关注美联储的降息节奏对全球流动性的影响。国内方面，上半年经济运行稳中有进，但抢出口效应消退后外需的持续性有待观察，下半年出口不确定性或有所增加。国内政策空间依然充裕，扩内需政策有望继续发力。后续关注国内政策出台和实施的节奏、力度与效果，持续跟踪国内经济基本面的修复情况。  国内权益市场主要指数估值目前处于相对合理区间。三季度A股上市公司半年报进入集中披露期，短期内市场行情或转向盈利增长驱动，景气度持续向好的板块有望获得投资者关注。长期来看，国内经济走势和企业盈利变化仍是影响权益市场表现的关键因素。","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2025年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1343363","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb059972e","date":"2025-03-30T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2025年一季度，海外方面，美联储暂停降息，市场对于美国经济放缓和通胀担忧提升，叠加美国关税政策加剧全球贸易不确定性，美股出现回调，美债利率、美元指数回落，避险情绪推动黄金价格上行。国内方面，国家统计局发布1-2月经济数据，经济运行总体保持平稳。消费维持韧性，固定资产投资增速回升，财政发力下广义基建投资增速维持高位，房地产投资降幅收窄，随着一系列政策效果逐步显现，经济有望延续企稳改善态势。  报告期内，A股市场总体呈现震荡格局。上证指数下跌0.48%，沪深300指数下跌1.21%，中证500指数上涨2.31%。从行业上来看，有色金属、汽车、机械设备、计算机等行业涨幅居前，而煤炭、商贸零售等行业表现较弱。人工智能技术引领的全球科技创新仍在持续，全球资金对中国科技资产的看法也出现了积极转变。报告期内，小盘风格、成长风格表现相对占优，而防御型红利资产阶段性承压。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购，力争获取收益增厚的机会。","declarationDate":"2025-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.037Z","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2025年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1268245","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb059972d","date":"2024-12-30T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2024年，美联储开启降息周期，外部流动性压力有所缓解。国内政策陆续释放积极信号，房地产政策持续优化，货币政策、财政政策发力，多地推出以旧换新政策助力消费，稳增长预期逐步增强。四季度化债资金的落地，有助减轻地方政府财政压力。一揽子增量政策效果逐步显现，高频经济数据上出现一些积极信号，房地产销售、消费等数据阶段性回暖，经济整体呈现修复态势。  报告期内，A股市场整体波动较大，9月下旬市场快速反弹，之后整体呈现震荡格局。报告期内，A股主要宽基指数普遍上涨，上证指数上涨12.67%，沪深300指数上涨14.68%，中证500指数上涨5.46%，全年来看大盘风格表现相对占优。从行业上来看，银行、非银金融、通信、家用电器、电子等行业涨幅居前，而医药生物、农林牧渔、美容护理、食品饮料等行业表现较弱。在前期市场震荡调整的过程中，红利资产表现出较好的防御属性。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购力争提高基金收益。","declarationDate":"2025-01-20T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.034Z","mo":"海外方面，2024年9月份美国正式启动降息，但美国通胀韧性仍存，可能制约着美联储降息节奏。国内经济延续复苏趋势，但仍面临不少困难和挑战，国内政策有望继续发力。2024年12月中央政治局会议和中央经济工作会议政策定调积极，提出要实施更加积极的财政政策和适度宽松的货币政策。后续更多领域的支持政策值得期待。对于政策的实施和影响，需持续观察国内经济复苏情况。随着外部环境缓和、内生动能逐步恢复，预计国内经济将延续企稳回升态势。  A股市场经过2024年9月下旬快速上涨后，估值水平已恢复到长期历史中位水平，但经济预期尚未完全扭转。随着经济基本面继续企稳向上，投资者信心进一步恢复，2025年A股市场可能逐步转换为盈利增长驱动的行情。","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2024年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1247940","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb059972c","date":"2024-09-29T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2024年三季度，海外方面，美联储降息50个基点超市场预期，美国经济“软着陆”预期有所强化。国内方面，经济仍在修复过程中，出口韧性仍在，但外需整体边际走弱，工业生产、消费拉动不足，基建投资增速有所放缓，房地产投资继续承压。9月下旬针对宏观经济、房地产及资本市场的一系列增量政策密集出台，政策层面向市场释放积极信号。后续仍需密切关注经济基本面改善情况。  报告期内，A股市场大部分时间呈现震荡调整，季末政策出台后市场预期改善，成交量放大，各指数普遍快速上涨。报告期内，上证指数上涨12.44%，沪深300指数上涨16.07%，中证500指数上涨16.19%。分行业来看，非银金融、房地产、商贸零售等行业表现较好，而煤炭、石油石化、公用事业等行业表现较弱。从风格上看，在季末上涨过程中成长风格相对占优，而周期相对表现较弱。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购力争提高基金收益。","declarationDate":"2024-10-23T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.032Z","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2024年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1170777","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb059972b","date":"2024-06-29T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2024年上半年，海外方面，美国通胀有所缓和，但美联储降息预期反复波动，美债利率仍在高位运行。国内方面，经济继续修复，社零边际改善，外需拉动下出口表现较好，制造业韧性较强，而基建增速略有放缓，房地产投资仍然承压。房地产政策持续优化，对稳定市场预期有一定积极作用。  报告期内，A股市场经历年初调整后反弹修复，之后总体呈现弱势震荡格局，二季度成交额有所下降，市场整体风险偏好回落。上证指数下跌0.25%，沪深300指数上涨0.89%，中证500指数下跌8.96%。分行业来看，银行、煤炭、公用事业、家用电器、石油石化等行业表现较好，而计算机、商贸零售、社会服务、传媒、医药生物等行业跌幅较大。从风格上看，在经济总量弹性较为缺乏的背景下，大盘和红利风格相对占优。从量化角度看，市场存量博弈格局之下，基本面因子如价值因子等表现较强。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购力争提高基金收益。","declarationDate":"2024-07-17T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.029Z","mo":"展望2024年下半年，全球通胀压力有望继续缓和，海外经济面临下行压力，美联储降息时点临近，或利于外部流动性改善和风险偏好提振。国内仍处于经济修复期，但面临有效需求不足、社会预期偏弱等挑战，国内政策有望继续发力，政策的实施和影响、基本面恢复有待进一步观察。随着外部环境缓和、内生动能逐步恢复，预计国内经济将延续企稳回升态势。  随着经济预期改善、资本市场制度不断完善，投资者信心也将逐渐恢复，A股市场也有望逐步企稳。整体来看，经过震荡回调后目前A股估值水平处于历史较低水平，权益资产具备较好的配置性价比。新质生产力、高端制造和国企改革等结构性投资机会可能进一步增加。","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2024年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1142349","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb059972a","date":"2024-03-30T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2024年一季度，海外方面，美国保持经济韧性和通胀粘性，市场对美联储降息预期的博弈持续，美债利率震荡上行。国内方面，国内经济继续修复，从1-2月经济数据来看，出口表现较强，居民消费维持韧性，固定资产投资中制造业投资复苏，而地产整体表现仍偏弱。政策方面，国内宏观政策调控力度加大，央行下调存款准备金率0.5%，5年期以上LPR下调25个基点，房地产政策持续优化。  报告期内，A股市场经历年初调整后反弹修复，上证指数上涨2.23%，沪深300指数上涨3.10%，中证500指数下跌2.64%，创业板指数下跌3.87%。其中，银行、石油石化、煤炭、家用电器、有色金属等行业表现较好，而医药生物、计算机、电子等行业跌幅较大。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购力争提高基金收益。","declarationDate":"2024-04-18T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.027Z","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2024年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1067145","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb0599729","date":"2023-12-30T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2023年，海外方面，美国经济韧性仍存，通胀从高位逐步回落，美债利率走高至10月开始下行，降息预期逐渐升温。国内方面，经济企稳回升，供给和需求均有所改善。工业生产逐步回升，工业企业效益有所改善；消费市场恢复向好，特别是服务消费回暖较快；基建投资和制造业投资仍保持韧性。政策方面，国内宏观政策维持积极，房地产政策持续优化。  报告期内，A股市场总体呈现震荡调整格局，上证指数下跌3.70%，沪深300指数下跌11.38%，中证500指数下跌7.42%，创业板指数下跌19.41%。全年来看，通信、传媒、计算机、电子等行业表现较好，而美容护理、商贸零售、房地产、电力设备等行业跌幅较大。下半年以来市场风险偏好有所下行，特别是人工智能技术落地进程与市场预期存在差异，部分科技行业调整幅度较大。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购力争提高基金收益。","declarationDate":"2024-01-18T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.024Z","mo":"对于很多A股投资者来说，2023年可能是投资上比较艰难的一年：外部环境不确定性上升，赚钱效应减弱，A股市场处于存量博弈状态。展望2024年，全球通胀压力有望继续缓和，海外经济面临下行压力，美联储降息预期逐渐升温，利于外部流动性改善和风险偏好提振。国内或将进一步强化宏观政策逆周期和跨周期调节，继续实施积极的财政政策。随着外部环境缓和、内生动能逐步恢复，国内经济有望延续企稳回升态势。  国内经济走势和企业盈利变化将是影响2024年A股市场重要因素。随着经济预期改善与企业盈利修复，投资者信心也将逐渐恢复。我们认为，目前A股整体估值水平处于较低水平，权益资产具备较好的配置性价比。在国内外流动性共振宽松情况下，A股投资环境或将有所改善，估值有望迎来修复。","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2023年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=1049955","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb0599728","date":"2023-09-29T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2023年三季度，海外方面，美国经济韧性仍存，叠加油价持续上行，对于美国通胀担忧和美联储加息预期有所反复，美元高利率环境可能会维持较长时间。国内方面，经济逐渐有边际回暖迹象，房地产政策持续优化，但地产销售仍需观察。国内货币政策维持宽松，8月央行下调MLF利率和逆回购利率，9月央行下调金融机构存款准备金率0.25个百分点。  报告期内，A股市场总体震荡调整。上证指数下跌2.86%，沪深300下跌3.98%，中证500下跌5.13%，创业板指下跌9.53%。其中，非银金融、煤炭、石油石化、钢铁、银行等行业涨幅居前，而电力设备、传媒、计算机、通信、国防军工等行业表现较差。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购力争提高基金收益。","declarationDate":"2023-10-23T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.021Z","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2023年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=984553","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb0599727","date":"2023-06-29T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2023年上半年，海外经济仍显韧性，美国通胀持续回落，核心通胀韧性较强但近期有所松动，美联储上半年加息3次，美债利率仍在相对高位运行。国内方面，上半年国内经济延续筑底恢复态势，基建投资同比增长仍维持较高水平，消费特别是服务类消费有所回暖，而房地产和出口承压。国内货币政策维持稳健宽松。  报告期内，A股市场先涨后跌总体呈现震荡格局，上证指数上涨3.65%，沪深300指数下跌0.75%，中证500指数上涨2.29%，创业板指数下跌5.61%。其中，通信、传媒、计算机等行业表现较好，而商贸零售、房地产、美容护理、建筑材料等行业跌幅较大。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购力争提高基金收益。","declarationDate":"2023-07-18T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.018Z","mo":"展望2023年下半年，美联储加息周期或将近尾声，后续美联储加息压力和预期也将有所缓和，利于外部流动性改善和风险偏好提振。近期稳增长政策陆续出台，未来国内货币政策、财政政策都存在发力的可能，市场对于经济增长的悲观预期有望逐步修正。  总体来说，当前国内经济复苏动能仍然偏弱，流动性仍然相对宽裕，权益市场面临的流动性环境仍相对比较友好。下半年投资环境或将有所改善，经济预期与风险偏好有望进一步修复。随着经济逐步企稳，上市公司盈利能力年内有望逐步改善。目前A股整体估值水平处于较低水平，权益资产具备较好的配置性价比。短期来看，预期改善之下国企改革板块和顺周期板块可能存在结构性机会。中长期来看，数字经济相关的TMT板块可能仍是市场比较关注的方向。","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2023年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=954054","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb0599726","date":"2023-03-30T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2023年一季度，海外方面，美联储2、3月各加息25bp，海外银行业风险持续暴露，3月美联储扩表为市场提供短期流动性支持。国内方面，一季度经济结构性复苏，1-2月固定资产投资同比增长5.5%，广义基建投资同比增长12.2%仍在高位，地产出现底部修复迹象，消费有所回暖。3月央行下调金融机构存款准备金率0.25个百分点，超市场预期。  报告期内，A股市场经历年初快速上涨，随后震荡小幅回调。上证指数上涨5.94%，沪深300上涨4.63%，中证500上涨8.11%，创业板指上涨2.25%。其中，计算机、传媒、通信、电子、建筑装饰等行业涨幅居前，而房地产、商贸零售、银行等行业表现较差。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购力争提高基金收益。","declarationDate":"2023-04-19T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.015Z","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2023年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=879038","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb0599725","date":"2022-12-30T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2022年，海外方面，欧美高通胀持续发酵，海外流动性收紧，到四季度美国通胀数据有所改善，美联储加息压力缓和，而海外对于经济衰退的担忧逐渐提升。国内方面，流动性环境总体维持适度宽松。国内经济增长面临压力较大，下半年经济缓慢筑底修复，其中基建投资成为经济亮点、维持较高增速。随着四季度各项政策落地，房地产和消费修复的预期有所改善。  报告期内，A股市场在去年经过四个月左右的大幅调整后维持震荡格局。全年来看A股主要指数普遍下跌，上证指数跌幅15.13%，沪深300跌幅21.63%，中证500跌幅20.31%，创业板指跌幅29.37%。其中，煤炭行业表现较好，而电子、建筑材料、传媒、计算机、电力设备、国防军工等行业跌幅较大。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购力争提高基金收益。","declarationDate":"2023-01-16T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.013Z","mo":"展望2023年，国内外宏观经济形势可能会发生明显变化。海外方面，经济可能面临从通胀到衰退的挑战，海外流动性可能逐步转向宽松。对我国而言，输入性通胀压力和人民币汇率压力有望得到缓解，但海外经济下行可能对我国出口带来较大压力。国内方面，去年四季度的各项政策措施效果预计将在今年有所体现。随着房地产市场的回暖、消费场景和需求的恢复，国内经济有望逐步复苏。同时，我国高端制造业面临的供应链安全挑战日益严峻，科技制造产业短期内或将承压，而长期来看有望促进产业重要环节的国产化进程，可能促使我国在全球产业链分工中有所突破。  往后看，总体来说投资环境或将有所改善，经济预期与风险偏好有望进一步修复。国内流动性预计仍将维持合理充裕，权益市场面临的流动性环境仍相对比较友好。A股整体盈利承压短期内可能延续，但随着经济逐步企稳，上市公司盈利能力今年有望逐步改善。我们认为，经过2022年的市场调整，A股整体估值水平处于较低区间，权益资产具备较好的性价比，中长期资金或将开始重新配置。今年在国内经济复苏预期下，A股有望成为全球资金的配置方向。","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2022年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=872018","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb0599724","date":"2022-09-29T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2022年三季度，海外通胀维持高位、美联储加息压力仍存，对于海外经济衰退的担忧持续。国内方面，国内经济缓慢恢复，其中基建投资成为近期亮点，7、8月广义基建投资同比增速分别为11.5%、15.4%。前期稳增长政策逐步落地见效，专项债持续形成实物工作量，支撑基建投资维持较高增速。国内流动性环境维持宽松，8月份央行政策利率和LPR下调，有效降低融资成本。在信贷需求比较低迷的情况下，利率下调有助于刺激社会中长期需求，稳定房地产的预期；另一方面维护流动性宽松的预期，对市场风险偏好也有所支撑。报告期内，A股市场整体震荡下行，成交额有所下降。其中，煤炭、公用事业等行业表现相对较好，而建筑材料、电力设备、电子等行业表现相对一般。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回需求，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购力争提高基金收益。","declarationDate":"2022-10-24T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.010Z","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2022年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=803763","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb0599723","date":"2022-06-29T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2022年上半年，海外高通胀持续发酵、流动性收紧趋势加快。国内方面，上半年国内经济面临压力，受疫情影响2季度经济走弱，国内流动性环境总体维持宽松。  报告期内，A股市场先跌后涨，市场持续调整至4月下旬低点后逐步企稳反弹。上证指数跌幅6.63%，沪深300跌幅9.22%，中证500跌幅12.30%，创业板指跌幅15.41%。其中，煤炭行业收益居前，而电子、计算机、传媒、国防军工等行业表现较差。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金通过参与网下新股申购以提高基金收益。","declarationDate":"2022-07-19T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.007Z","mo":"展望2022年下半年，国内外宏观经济形势对比可能会发生变化。海外方面，流动性持续收紧，对经济压力有所增加，市场对于美国经济衰退的担忧抬升。国内方面，随着疫情后消费恢复和输入性通胀影响减弱，国内经济内外部压力有所缓解。今年新增专项债在 6 月底前基本发行完毕，下半年转化为实物工作量有望对宏观经济形成支撑。  总体来看，目前A股市场估值水平处于合理区间，但行业之间的估值分化有所加大。预计下半年国内权益市场面临的流动性环境仍相对比较友好，市场风险偏好仍处于修复过程中。下半年A股有望保持韧性，市场或以结构性机会为主，可关注估值调整合理并且有望持续兑现基本面的行业。长期来看，中国经济发展模式从高增长转变为高质量发展，居民资产配置也或将从以房地产为主逐步转向资本市场，A股具备长期配置价值和投资机会。","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2022年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=779125","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb0599722","date":"2022-03-30T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2022年一季度，海外高通胀持续发酵，无风险利率抬升，流动性预期收紧，引发市场剧烈反应。俄乌地缘冲突升级，全球风险偏好受到压制，石油价格冲高后回落。国内方面，通胀有所缓和，1-2月国内经济数据发布，数据超出市场预期。但3月以来国内疫情反复对生产和消费有所拖累，从中微观数据上看预计一季度经济仍存在一定压力，政策仍存在宽松窗口 报告期内，A股总体出现较大幅度回调。上证指数下跌-10.65%，沪深300下跌-14.53%，中证500下跌-14.06%，创业板指下跌-19.96%。其中，煤炭、房地产、银行等行业涨幅居前，而电子、国防军工、汽车、家用电器、食品饮料等行业表现较差。 本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金积极参与网下新股申购，以提高基金收益。","declarationDate":"2022-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.004Z","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2022年第1季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=722967","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f17fea5b3eb0599721","date":"2021-12-30T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2021年，全球经济延续复苏，大宗商品价格持续走高，海外主要经济体通胀数据攀升，宏观政策温和收缩。国内经济上半年复苏较为稳健，下半年受到极端天气、疫情反复等因素的拖累经济增长有所回落，经济内生动能逐渐趋缓。  报告期内，A股市场呈震荡上行格局，行业分化较为明显。上证指数上涨4.80%，沪深300下跌-5.20%，中证500上涨15.58%，创业板指上涨12.02%，其中电力设备、有色金属、煤炭、基础化工、钢铁等行业涨幅居前，而家用电器、非银金融、房地产、社会服务、食品饮料等行业表现较差。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金积极参与网下新股申购，以提高基金收益。","declarationDate":"2022-01-20T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:01.001Z","mo":"展望2022年，全球后疫情时代逐步到来，随着美联储量化宽松政策的退出，海外经济复苏力度可能逐渐减弱，同时全球金融市场的流动性也将受到一定制约。国内方面，去年底中央经济工作会议定调经济发展面临需求收缩、供给冲击和预期转弱三重压力，对经济形势判断较为严峻，强调积极的财政政策和灵活适度的货币政策。  疫情影响对国内制造业带来的红利正逐步减弱，2022年国内经济面临较大下行压力。年初以来逆周期调控预期持续升温，市场面临增长动能放缓和稳增长政策预期的博弈，叠加海外流动性收紧的压力，年内A股市场整体波动可能仍然较大，市场风格更趋于均衡。A股市场经过年初的调整，各行业板块估值有不同程度的回落，总体来看A股市场目前估值水平处于合理区间。长期来看，中国经济发展模式从高增长转变为高质量发展，居民资产配置也将从以房地产为主逐步转向资本市场，A股具备长期配置价值和投资机会。","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2021年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=715689","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f07fea5b3eb0599720","date":"2021-09-29T16:00:00.000Z","stockId":3000000165519,"sao":"回顾2021年三季度，全球经济延续复苏，但部分国家和地区的疫情仍然较为严峻。国内经济数据超预期回落，极端天气、疫情反复、大宗价格高位等因素拖累工业生产，国内经济下行压力较大。从中报上看，企业盈利复苏较为强劲，中小市值公司业绩加速复苏。在资金存量博弈环境下，A股市场维持震荡格局。  报告期内，A股总体维持震荡，成交量较前期有所上升，小盘股表现优于大盘股。上证指数下跌-0.64%，沪深300下跌-6.85%，中证500上涨4.34%，创业板指下跌-6.69%，其中采掘、公用事业、有色金属、钢铁、化工等行业涨幅居前，而医药生物、休闲服务、食品饮料、传媒、家用电器等行业表现较差。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成分股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金积极参与网下新股申购，以提高基金收益。","declarationDate":"2021-10-26T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:00.998Z","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2021年第3季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=656633","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f07fea5b3eb059971f","date":"2021-06-29T16:00:00.000Z","stockId":3000000165519,"sao":"回顾今年上半年，全球经济延续复苏趋势，大宗商品价格持续走高，主要经济体通胀数据攀升，但中美两国货币政策均未释放明显的收紧信号。我国宏观经济稳定复苏，上半年GDP同比增长12.7%，通胀水平明显回升。  报告期内，A股市场总体呈现区间震荡格局，小盘股表现优于大盘股，成长风格相对占优。上证指数上涨3.40%，沪深300上涨0.24%，中证500上涨6.93%，创业板指上涨17.22%，其中电气设备、钢铁、化工、采掘、有色金属等行业涨幅居前，而家用电器、非银金融、国防军工、房地产、农林牧渔等行业表现较差。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成份股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金积极参与网下新股申购，以提高基金收益。","declarationDate":"2021-07-19T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:00.995Z","mo":"展望下半年，全球经济复苏态势预计将延续，疫情防控形势将持续影响全球经济复苏情况。通胀与货币政策取向仍然是影响下半年宏观流动性的最主要因素，美联储流动性的边际收紧渐行渐近，各类资产价格的波动可能进一步加剧。国内经济有望率先重归疫情前的增长轨道，复苏温和放缓，主要动能由外需逐步切换为内需，行业景气度走势的分化将会更加明显。  展望后市，权益市场短期波动可能加大，A股缺乏整体趋势性估值提升的推动力，震荡局面或将持续，我们对于部分高估值权益资产走势相对比较谨慎，成长风格及高景气产业链仍存在结构性机会。","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2021年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=629078","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f07fea5b3eb059971e","stockId":3000000165519,"sao":"回顾2021年一季度，海外疫情有所缓和、疫苗覆盖率逐步提升，全球复苏趋势延续。整体来看经济动能较强，需求的修复带动大宗商品价格上涨，宏观政策温和收缩，市场资金相对较为充裕，再通胀交易加速兑现。A股市场前期估值结构分化较为严重，风格切换下市场波动加剧。报告期内，A股市场呈震荡格局。上证指数下跌0.90%，沪深300下跌3.13%，中证500下跌1.78%，创业板指下跌7.00%，其中钢铁、公用事业、银行、休闲服务、建筑装饰等行业涨幅居前，而国防军工、非银金融、通信、计算机、传媒等行业表现较差。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成份股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金积极参与网下新股申购，以提高基金收益。","date":"2021-03-30T16:00:00.000Z","declarationDate":"2021-04-20T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:00.992Z","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"中信保诚中证800医药指数型证券投资基金（LOF）2021年第一季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=571073","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f07fea5b3eb059971d","stockId":3000000165519,"sao":"回顾2020年，受新冠疫情影响，我国经济遭遇了重大挑战。一季度国内经济受疫情冲击呈现断崖式下跌，宏观政策逆周期调控持续发力，流动性维持宽裕，推动国内经济改善。得益于有力的疫情防控，国内复工复产逐步推进，二季度开始经济数据明显好转；海外疫情不断扩散和反复，出口、进口替代也持续拉动国内经济的增长，国内经济逐步回到正常水平。  报告期内，上证指数上涨13.87%，沪深300上涨27.21%，中证500上涨20.87%，创业板指上涨64.96%，其中休闲服务、电气设备、食品饮料等行业涨幅居前，而房地产、通信、建筑装饰等行业表现较差。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成份股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金积极参与网下新股申购，以提高基金收益。","date":"2020-12-30T16:00:00.000Z","declarationDate":"2021-01-21T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:00.990Z","mo":"展望2021年，随着新冠疫苗接种的推进，全球经济活动有望逐步回归正常化，叠加补库存需求推动经济增长，全球复苏将是大概率的事件。在本轮疫情冲击下，海内外供给和需求错配为中国出口产业优化全球竞争格局提供了重大机会，海外复苏还将继续拉动中国经济的外需增长；国内经济复苏和企业盈利修复的趋势将延续，在需求端、制造业投资驱动下，有望和海外复苏形成共振。宏观政策今年大概率将稳步转向，货币政策经过年初宽松窗口后有再度收紧的风险，值得密切关注。  去年在宽松流动性支持下，A股龙头公司估值持续抬升，市场内估值结构分化较为严重，部分景气度向好的板块和个股当前估值处于历史高位。2021年A股市场整体波动可能加大，我们对于部分高估值权益资产走势相对比较谨慎，未来需要从更长期角度寻找成长空间较大、估值处于合理区间的优质资产。","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"信诚中证800医药指数分级证券投资基金2020年年度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=549971","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f07fea5b3eb059971c","stockId":3000000165519,"sao":"回顾三季度，国内疫情与经济形势逐步趋于缓和，但从全球的角度看，疫情影响在各地仍有反复，加大了全球经济复苏的不确定性。影响经济的另一个比较重要的因素来源于美国大选。截至10月，美国选情仍处于焦灼状态，哪党上台可能会对中国对外经贸政策产生很大影响，进而影响到本国货币政策和利率。A股市场三季度，下跌较快的是通信、计算机与商贸板块；上涨较快的是新能源板块，包括新能源车产业链、以及光伏风电等。前三季度，上证综指涨幅5.51%、深证成指涨幅23.74%、创业板指涨幅43.19%。  三季度进出口数据持续回升，主要由于内需与外需的改善。经济数据方面，中国上半年GDP实际同比增3.2%，经济恢复向好的势头有望持续；宽信用的政策带动社融数据显著回升并构造了流动性宽松的市场环境，其中社融增速主要由人民币贷款和政府债券支撑；上半年CPI逐月走低，而近期CPI有所回升的主要原因在于洪灾导致的猪肉价格和农产品价格上涨，结合经济回升的现状来看通胀压力并不大；制造业PMI连续五个月维持在50以上，表明经济仍在好转。然而需关注中美关系的后续发展，上半年中美互关领事馆以及近期南海与台海问题、美国大选等事件均导致中美关系的不确定性有所上升，国际贸易摩擦加剧，需关注国际形势给A股市场带来的不确定性。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成份股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金积极参与网下新股申购，以提高基金收益。  展望未来，总体来说我们更加看好估值处于合理区间的行业龙头。从疫情中复工是中国相对世界其他国家更具确定性的情况，因此全球资本流入是大势所趋。风险在于中美的大国博弈或能产生对中国较为负面的影响。  从行业角度看，下半年我们持续看好消费、医药以及电子科技对股市的带动作用，同时会关注低估值行业的中短期回暖，比如金融板块中的非银板块，以及周期性板块。对于科创板以及未来创业板的改革抱有正向预期，未来将长期持有在科创板及创业板上市的科技龙头企业。  我们坚持以“价值”作为投资，看好未来在各行业聚集效用，做价值股的长期投资。","date":"2020-09-29T16:00:00.000Z","declarationDate":"2020-10-27T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:00.987Z","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"信诚中证800医药指数分级证券投资基金2020年第三季度报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=493036","linkType":"PDF","source":"csrc_pdf"}},{"_id":"69aed8f07fea5b3eb059971b","stockId":3000000165519,"sao":"2020年上半年，国内经济形势逐步缓和。随着全球复产复工，经济面受到的主要影响因素：新冠疫情对经济的影响处于逐步缓和的状态。上半年，医药、半导体、消费仍然是领涨行业；而休闲娱乐随着免税开放的政策落地也大幅拉升；周期、金融在上半年中表现不佳。上半年，上证综指涨幅-0.79%、深证成指涨幅16.13%、创业板指涨幅35.6%。  2020年上半年宏观数据较为乐观，二季度GDP实际同比增3.2%，经济恢复向好的势头有望持续；宽信用的政策带动社融数据显著回升并构造了流动性宽松的市场环境，其中社融增速主要由人民币贷款和政府债券支撑；上半年CPI逐月走低，而近期CPI有所回升的主要原因在于洪灾导致的猪肉价格和农产品价格上涨，结合经济回升的现状来看通胀压力并不大；制造业PMI连续五个月维持在50以上，表明经济仍在好转。国内经济整体复苏共同导致工业金属需求增加，而南美疫情导致部分工业金属供给端收紧，配合国内流动性宽松的大环境，有色板块近期上涨较多。然而需关注中美关系的后续发展，中美互关领事馆等事件导致中美关系的不确定性有所上升，国际贸易摩擦加剧，需关注国际形势给A股市场带来的不确定性；同时，国内避险情绪升温也导致了黄金白银等贵金属持续走强。  本基金跟踪的标的指数为中证800制药与生物科技指数。报告期内，本基金坚持既定的指数化投资策略，原则上按照标的指数中成份股组成及其权重构建股票投资组合，实现对标的指数的有效跟踪。本基金认真应对投资者日常申购、赎回，根据市场情况、成分股停复牌等合理安排权益仓位和头寸，有效管理跟踪误差。本基金积极参与网下新股申购，以提高基金收益。","date":"2020-06-29T16:00:00.000Z","declarationDate":"2020-07-20T16:00:00.000Z","lastUpdated":"2026-03-09T14:28:00.984Z","mo":"展望未来，总体来说我们更加看好估值处于合理区间的行业龙头。从疫情中复工是中国相对世界其他国家更具确定性的情况，因此全球资本流入是大势所趋。风险在于中美的大国博弈或能产生对中国较为负面的影响。  从行业角度看，下半年我们持续看好消费、医药以及电子科技对股市的带动作用，同时会关注低估值行业的中短期回暖，比如金融板块中的非银板块以及周期股。对于科创板以及未来创业板的改革抱有正向预期，未来将长期持有在科创板及创业板上市的科技龙头企业。  我们坚持以“价值”作为投资，看好未来在各行业聚集效用，做价值股的长期投资。","fund":{"_id":3000000165519,"stockCode":"165519","stockType":"fund","areaCode":"cn","followedNum":41,"blackenedNum":0,"status":"normal","exchange":"sz","fundType":"stock","ipoDate":"2013-07-21T16:00:00.000Z","setUpScale":337141000,"market":"a","tickerId":165519,"custody":"中国银行股份有限公司","name":"中信保诚中证800医药指数型证券投资基金（LOF）","shortName":"中信保诚中证800医药指数（LOF）(165519)","fundSecondLevel":"company","lastUpdated":"2026-05-15T17:12:09.994Z","__csrcFundId":3466,"fundStatus":"normal","masterFundFlag":1,"inceptionDate":"2013-08-15T16:00:00.000Z","fundCollectionId":4000050490000,"currency":"CNY","masterFundShortName":"中信保诚中证800医药指数（LOF）","pinyin":"zxbczz800yyzsxzqtzjj(lof)","__indexSourceEastMoney":1,"__indexSourceCsi":1,"indexFundFlag":1,"indexId":1000000000841,"lofFundFlag":1,"managers":[{"stockCode":"8801601333","stockType":"fund_manager","exchange":"fm","tickerId":826180280,"name":"黄稚"}]},"announcement":{"linkText":"信诚中证800医药指数分级证券投资基金2020年中期报告","linkUrl":"http://eid.csrc.gov.cn/fund/disclose/instance_show_pdf_id.do?instanceid=454856","linkType":"PDF","source":"csrc_pdf"}}]}